CANY
ADPT icon

Caxton Associates (New York)’s Adaptive Biotechnologies ADPT Stock Holding History

Caxton Associates (New York)’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$739K Buy
+123,287
New +$680K 0.02% 265
2022
Q2 		– Sell
-30,690
Closed -$426K – 546
2022
Q1 		$426K Buy
+30,690
New +$483K 0.03% 285

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Caxton Associates (New York)'s ADPT Position: Q4 2024 in Review

Caxton Associates (New York) opened a new position in Adaptive Biotechnologies (ADPT) in Q4 2024: 123,287 shares worth $739K. The stake represents 0.02% of the portfolio and ranks #265 among its holdings. This is a return to the name: Caxton Associates (New York) previously reported a position in ADPT as recently as Q1 2022.

Caxton Associates (New York) first reported a position in ADPT in Q1 2022 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

  • Caxton Associates (New York) held 123,287 shares of Adaptive Biotechnologies worth $739K as of Q4 2024.
  • Adaptive Biotechnologies was a new Caxton Associates (New York) position in Q4 2024.
  • Adaptive Biotechnologies made up 0.02% of Caxton Associates (New York)'s portfolio in Q4 2024, its #265 holding.
  • Caxton Associates (New York) first reported a position in Adaptive Biotechnologies in Q1 2022 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.